To view or add a comment, sign in Imagine a tool that can help you track market dynamics for GLP-1 prescriptions, analyze the provider types initiating these prescriptions, and visualize regional trends
Rather than relying on guesswork, patients can receive guidance based on their individual situation
In murine CM, kininogen, prekallikrein, prolylcarboxypeptidase, or bradykinin receptor deficiency ameliorates the disorder
No significant endocrine adverse events were reported, consistent with its selective pharmacological profile
The pharmacokinetic reasoning supports this (bypassing gut bacteria), but head-to-head comparisons of TMAO levels between routes have not been conducted in the context of compounded tirzepatide
This opens the door to a new era of oral small molecule therapies that target the well-validated GLP-1R pathway for metabolic health